Recombinant Human ST6GAL1 (C-6His)

Description

EnkiLife provides the Recombinant Human ST6GAL1 (C-6His) protein,aslo know as Beta-Galactoside Alpha-2,6-Sialyltransferase 1,Alpha 2;6-ST 1,B-Cell Antigen CD75,CMP-N-Acetylneuraminate-Beta-Galactosamide-Alpha-2,6-Sialyltransferase 1,ST6Gal I,ST6GalI,Sialyltransferase 1,ST6GAL1,SIAT1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Beta-Galactoside Alpha-2,6-Sialyltransferase 1 is produced by our Mammalian expression system and the target gene encoding Lys27-Cys406 is expressed with a 6His tag at the C-terminus.Accession:P15907. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:44.6 KDa. Background:The ST6GAL1 gene encodes β-Galactosamide α-2,6-Sialyltransferase 1. It is a type II membrane protein and is localized to the trans-Golgi network. It catalyzes 2,6-sialylation of Galβ1,4-GlcNAc structures on N-glycans. ST6GAL1 is highly expressed in the liver and other tissues. ST6GAL1 deficiency causes abnormalities in B-cell immunoreactivity. The expression and activity of ST6GAL1 are associated with tumor metastasis in breast and colon cancers. The majority of ST6GAL1 in the liver is cleaved and secreted into the serum and may be used as a biomarker for hepatitis diseases.